MedTrace Logo

Iressa Versus Docetaxel (Taxotere)

NCT00076388 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1440

Last updated 2011-05-13

No results posted yet for this study

Summary

The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy.

Conditions

  • Non-Small-Cell Lung Carcinoma

Interventions

DRUG

Gefitinib

DRUG

Docetaxel

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Iressa Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2007-03-31
Completion
2007-10-31

Countries

  • United States
  • Argentina
  • Belgium
  • Brazil
  • Canada
  • China
  • Croatia
  • Denmark
  • Estonia
  • France
  • Germany
  • Hong Kong
  • Indonesia
  • Italy
  • Latvia
  • Malaysia
  • Mexico
  • Philippines
  • Singapore
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Thailand
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00076388 on ClinicalTrials.gov